Investigating how a specific gene affects nicotine withdrawal in the brain.
Role of Dynamic Signaling of NRG3-ErbB4 in the Prefrontal Cortex in Mediating Nicotine Withdrawal Phenotypes
['FUNDING_FELLOWSHIP'] · UNIVERSITY OF KENTUCKY · NIH-11015770
This study is looking at how certain genes in the brain might affect how people feel and behave when they stop using nicotine, with the hope of finding new ways to help people quit smoking.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF KENTUCKY (nih funded) |
| Locations | 1 site (LEXINGTON, UNITED STATES) |
| Trial ID | NIH-11015770 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of the Neuregulin 3 (NRG3) gene and its receptor ErbB4 in the prefrontal cortex during nicotine withdrawal. By using a genetic mouse model, the study aims to explore how variations in these genes influence behavioral responses to nicotine dependence and withdrawal. The researchers will analyze the specific contributions of ErbB4 to nicotine withdrawal behaviors and examine the molecular changes that occur in the brain during chronic nicotine exposure and withdrawal. This approach could lead to new insights into potential therapies for smoking cessation.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals struggling with nicotine dependence or those interested in smoking cessation.
Not a fit: Patients who do not smoke or are not interested in quitting smoking may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective treatments for nicotine addiction and improved smoking cessation strategies.
How similar studies have performed: Other research has shown promise in exploring genetic factors related to nicotine dependence, suggesting that this approach could yield valuable insights.
Where this research is happening
LEXINGTON, UNITED STATES
- UNIVERSITY OF KENTUCKY — LEXINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PRANTZALOS, EMILY — UNIVERSITY OF KENTUCKY
- Study coordinator: PRANTZALOS, EMILY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: addictive disorder